Effects of PAP Treatment of OSA in Patients With Heart Failure

Inclusion Criteria:

18 and < 75 years of age.
Apnea-hypopnea index (AHI) of at least 15/hr based on overnight polysomnography.
New York Heart Association Class 3 or less.
LV ejection fraction <45% based on a prior imaging study (as measured within one year of baseline studies).
Absence of exacerbation of heart failure requiring hospitalization within the previous 3 mos.
Optimal pharmacologic therapy at the highest tolerated dose [3].

Exclusion Criteria:

Use of anti-diabetic medications
Primary valvular heart disease
Unstable angina
Myocardial infarction, cardiac surgery, or revascularization procedure within the previous 3 months
Uncontrolled hypertension defined as systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg.
Active smoking (Patient should not have smoked for at least 1 month prior to baseline studies and has the intention not to smoke for the duration of the study period)
Use of illicit drugs
Current use of home oxygen therapy
Requirement for a bi-level machine to treat sleep apnea
Use of corticosteroids
Creatinine clearance < 30ml/min (calculated from serum creatinine)
Pregnant women will be excluded as pregnancy interferes with glucose and adiponectin. Additionally the contrast used in the cardiac MRIs may be harmful to unborn babies. Females of child bearing potential must agree to use effective contraception during the trial.
Any contraindication to CMR (Cardiovascular magnetic resonance) imaging such as ferromagnetic foreign body, orbital metal, cerebral aneurysm clip, pacemaker, defibrillator, neurostimulator, allergy to gadolinium-based contrast, or severe claustrophobia. The standard FDA and OSUMC's screening guidelines for MRI safety will be followed.
Inability or unwillingness to provide consent